Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China
· Delayed Price · Currency is CNY 55.53
-0.24 (-0.43%)
At close: Apr 29, 2026
SHA:688192 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 291.42 | 250.16 | 74.2 | 121.67 | 364.24 | Upgrade
|
| Trading Asset Securities | 1,645 | 589.83 | 674 | 1,295 | 1,711 | Upgrade
|
| Cash & Short-Term Investments | 1,936 | 839.99 | 748.2 | 1,416 | 2,075 | Upgrade
|
| Cash Growth | 130.51% | 12.27% | -47.18% | -31.74% | 246.26% | Upgrade
|
| Accounts Receivable | 143.44 | 27.49 | 48.04 | - | 7.55 | Upgrade
|
| Receivables | 143.44 | 27.49 | 48.04 | - | 7.55 | Upgrade
|
| Inventory | 36.95 | 44.11 | 23.47 | 5.07 | - | Upgrade
|
| Other Current Assets | 66.03 | 87.37 | 90.65 | 51.64 | 29.57 | Upgrade
|
| Total Current Assets | 2,183 | 998.97 | 910.36 | 1,473 | 2,112 | Upgrade
|
| Property, Plant & Equipment | 381.23 | 243.91 | 102.26 | 103.66 | 104.48 | Upgrade
|
| Other Intangible Assets | 396.43 | 429.85 | 461.98 | 492.02 | 474.9 | Upgrade
|
| Long-Term Deferred Charges | 4.09 | 8.62 | 16.99 | 7.99 | 4.54 | Upgrade
|
| Other Long-Term Assets | 38.09 | 37.38 | 4.79 | 5.06 | 49.51 | Upgrade
|
| Total Assets | 3,003 | 1,719 | 1,496 | 2,082 | 2,746 | Upgrade
|
| Accounts Payable | 34.82 | 20.39 | 18.57 | 8.81 | 1.65 | Upgrade
|
| Accrued Expenses | 331.8 | 245.07 | 182.18 | 208.53 | 182.75 | Upgrade
|
| Short-Term Debt | 217.45 | 373.83 | 200.11 | - | - | Upgrade
|
| Current Portion of Long-Term Debt | 291.97 | 41.27 | 0.1 | - | - | Upgrade
|
| Current Portion of Leases | 21.2 | 23.53 | 22.95 | 21.34 | 16.84 | Upgrade
|
| Current Income Taxes Payable | 1.34 | - | 0.05 | 0 | - | Upgrade
|
| Current Unearned Revenue | 5.5 | 2.93 | 0.98 | - | - | Upgrade
|
| Other Current Liabilities | 81.14 | 78.06 | 23.49 | 9.82 | 10.76 | Upgrade
|
| Total Current Liabilities | 985.23 | 785.08 | 448.44 | 248.49 | 211.99 | Upgrade
|
| Long-Term Debt | 688.15 | 683.76 | 138.31 | - | - | Upgrade
|
| Long-Term Leases | 21.98 | 34.99 | 48.89 | 63.93 | 70.92 | Upgrade
|
| Long-Term Unearned Revenue | 11.48 | 14.84 | 12.11 | 11 | - | Upgrade
|
| Total Liabilities | 1,707 | 1,519 | 647.75 | 323.43 | 282.91 | Upgrade
|
| Common Stock | 461.19 | 417.65 | 408.15 | 407.16 | 404.18 | Upgrade
|
| Additional Paid-In Capital | 4,956 | 3,136 | 2,954 | 2,757 | 2,729 | Upgrade
|
| Retained Earnings | -4,124 | -3,360 | -2,514 | -1,406 | -669.85 | Upgrade
|
| Total Common Equity | 1,294 | 193.76 | 848.63 | 1,758 | 2,463 | Upgrade
|
| Minority Interest | 1.83 | 6.3 | - | - | - | Upgrade
|
| Shareholders' Equity | 1,296 | 200.06 | 848.63 | 1,758 | 2,463 | Upgrade
|
| Total Liabilities & Equity | 3,003 | 1,719 | 1,496 | 2,082 | 2,746 | Upgrade
|
| Total Debt | 1,241 | 1,157 | 410.37 | 85.27 | 87.76 | Upgrade
|
| Net Cash (Debt) | 695.51 | -317.39 | 337.83 | 1,331 | 1,987 | Upgrade
|
| Net Cash Growth | - | - | -74.62% | -33.02% | 231.62% | Upgrade
|
| Net Cash Per Share | 1.56 | -0.77 | 0.83 | 3.29 | 5.52 | Upgrade
|
| Filing Date Shares Outstanding | 461.19 | 417.65 | 408.15 | 407.16 | 404.18 | Upgrade
|
| Total Common Shares Outstanding | 461.19 | 417.65 | 408.15 | 407.16 | 404.18 | Upgrade
|
| Working Capital | 1,197 | 213.89 | 461.93 | 1,225 | 1,900 | Upgrade
|
| Book Value Per Share | 2.81 | 0.46 | 2.08 | 4.32 | 6.09 | Upgrade
|
| Tangible Book Value | 897.43 | -236.09 | 386.65 | 1,266 | 1,988 | Upgrade
|
| Tangible Book Value Per Share | 1.95 | -0.57 | 0.95 | 3.11 | 4.92 | Upgrade
|
| Buildings | 227.2 | - | - | - | - | Upgrade
|
| Machinery | 160.67 | 55.43 | 49.14 | 31.99 | 26.91 | Upgrade
|
| Construction In Progress | - | 169.72 | 13.35 | 8.85 | 5.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.